Hansoh Pharmaceutical Group Company Ltd
Hansoh Pharmaceutical Group's GHG Emissions Data Preview
In 2023, Hansoh Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Hansoh Pharmaceutical Group has also provided a category-level breakdown for 4 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Hansoh Pharmaceutical Group's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group amounted to 92,112.06 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group increased by 6.19%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Hansoh Pharmaceutical Group's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Hansoh Pharmaceutical Group's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Hansoh Pharmaceutical Group were 10,546.85 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Hansoh Pharmaceutical Group reduced its Scope 1 emissions over time?
Since 2021, Hansoh Pharmaceutical Group's Scope 1 emissions have increased by 68.59%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Hansoh Pharmaceutical Group's Scope 1 emissions increased by 16.87%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Hansoh Pharmaceutical Group's Scope 2 emissions?
In 2023, Hansoh Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 81,565.21 tCOâ‚‚e without specifying the calculation method.
Has Hansoh Pharmaceutical Group reduced its Scope 2 emissions over time?
Since 2021, Hansoh Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 29.73%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Hansoh Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hansoh Pharmaceutical Group 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Hansoh Pharmaceutical Group use for Scope 2 reporting?
In 2023, Hansoh Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.
Hansoh Pharmaceutical Group's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Hansoh Pharmaceutical Group's Value Chain Emissions
In 2023, Hansoh Pharmaceutical Group reported 51,543.36 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Hansoh Pharmaceutical Group includes a breakdown across 4 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2022, reflecting improved emissions accounting practices and greater transparency across the company's value chain
Hansoh Pharmaceutical Group's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Hansoh Pharmaceutical Group's Scope 3 emissions?
In 2023, Hansoh Pharmaceutical Group reported total Scope 3 emissions of 51,543.36 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2022), Hansoh Pharmaceutical Group's Scope 3 emissions increased by 258.3%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Hansoh Pharmaceutical Group disclose?
In 2023, Hansoh Pharmaceutical Group reported emissions for 4 out of the 15 Scope 3 categories defined by the GHG Protocol.
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Hansoh Pharmaceutical Group's Scope 3 emissions?
In 2023, the largest contributors to Hansoh Pharmaceutical Group's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 12,652.33 tCOâ‚‚e (83.13%)
- Capital Goods (Cat. 2): 2,071.33 tCOâ‚‚e (13.61%)
- Downstream Transportation and Distribution (Cat. 9): 267.13 tCOâ‚‚e (1.76%)
Hansoh Pharmaceutical Group's Scope 3 Emissions by Categories
Insights into Hansoh Pharmaceutical Group's Total Carbon Footprint
In 2023, Hansoh Pharmaceutical Group reported a total carbon footprint of 143,655.42 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 42.05% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Hansoh Pharmaceutical Group's total carbon footprint was Scope 2 emissions, accounting for 56.78% of the company's total carbon footprint, followed by Scope 3 emissions at 35.88%.